122 results
Page 4 of 7
8-K
gfvbxjc ko2jbtcbwzc
13 Dec 18
Millendo Therapeutics Announces Successful Merger Completion
4:08pm
8-K
EX-10.2
dfv3etfc7w
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
8-K
EX-10.3
hamgnds2b
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
8-K
EX-10.4
ita60bfkze3fwmaidw
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
DEFM14A
urzo9mvgtgx6fx6 d6
6 Nov 18
Proxy related to merger
12:00am
424B3
xeyq7obu6b219f va
5 Nov 18
Prospectus supplement
3:51pm
S-4/A
EX-8.1
30e2ji8leeuiibz 9lc
1 Nov 18
Registration of securities issued in business combination transactions (amended)
5:32pm
S-4/A
u4toq
1 Nov 18
Registration of securities issued in business combination transactions (amended)
5:32pm
S-4/A
EX-8.2
ewqvcd
1 Nov 18
Registration of securities issued in business combination transactions (amended)
5:32pm
8-K
EX-2.2
50lnq pywkp
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
8-K
EX-2.3
wbmggnk0yfn ryd
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
8-K
EX-2.1
as80qj2vh9grz6olt0yr
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
425
EX-2.1
jnkyur1b2
9 Aug 18
Business combination disclosure
5:17pm
425
EX-2.2
faiafivnmdidmkspf01
9 Aug 18
Business combination disclosure
5:17pm
425
EX-2.3
vaq8cgujd9s 4j
9 Aug 18
Business combination disclosure
5:17pm